Zanubrutinib: past, present, and future
In recent years, Bruton tyrosine kinase (BTK) inhibitors have provided significant advances
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …
in the treatment of patients with B-cell malignancies. Ibrutinib was the first BTK inhibitor to be …
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
A Wolska-Washer, T Robak - Frontiers in Oncology, 2023 - frontiersin.org
Zanubrutinib (BGB-3111, Brukinsa®, BeiGene) is a next-generation irreversible inhibitor of
Bruton's tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell …
Bruton's tyrosine kinase (BTK), developed by BeiGene in 2012 for the treatment of B-cell …
Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma
JP Alderuccio, IS Lossos - Expert review of hematology, 2023 - Taylor & Francis
Introduction Extranodal marginal zone lymphoma (EMZL) of mucosa-associated lymphoid
tissue is an indolent lymphoma originating from marginal zone B-cells and associated with …
tissue is an indolent lymphoma originating from marginal zone B-cells and associated with …
Management of Marginal Zone Lymphoma: A Canadian Perspective
A Peters, MM Keating, A Nikonova, S Doucette… - Current …, 2023 - mdpi.com
Marginal zone lymphomas (MZL) are a rare, heterogenous group of lymphomas, accounting
for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further …
for 5–17% of indolent non-Hodgkin lymphomas in the western world. They can be further …
Zanubrutinib: a novel therapeutic option for the treatment of B-cell neoplasms
A Majeranowski, F Lebiedziński… - Acta Haematologica …, 2023 - journals.viamedica.pl
Bruton's tyrosine kinase (BTK) is a part of the B-cell receptor (BCR) signaling pathway.
Activation of the BCR appears crucial for normal B cells as it regulates proliferation …
Activation of the BCR appears crucial for normal B cells as it regulates proliferation …
[引用][C] EXABS-223-IBCL Treatment Options for Marginal Zone Lymphoma
E Zucca - Clinical Lymphoma Myeloma and Leukemia, 2023 - Elsevier